Management of Palpitations in Children Starting Stimulant Medication for ADHD

Initial Assessment and Monitoring

The American Academy of Pediatrics recommends measuring heart rate and blood pressure immediately to quantify any changes from baseline in children who report palpitations after starting stimulant medication 1, 2
Stimulants typically cause mild, clinically insignificant increases averaging 1-2 beats per minute for heart rate and 1-4 mmHg for blood pressure 1, 2
A subset of 5-15% of children may experience more substantial increases in heart rate or blood pressure 1, 2

The American Academy of Pediatrics recommends obtaining or reviewing personal and family cardiac history elements, including specific cardiac symptoms and sudden unexplained death, especially in young family members 1, 2, 3, 4
If any cardiac risk factors are present, additional cardiac evaluation, including ECG, should be obtained, and pediatric cardiology referral should be considered before continuing stimulant medication 1, 2

Sudden cardiac death in children on stimulant medication is extremely rare 1, 2, 3, 4
Stimulant medications have not been shown to increase the risk of sudden death beyond that observed in children not receiving stimulants 1, 2, 4

For mild symptoms with normal cardiac history, the American Academy of Pediatrics recommends continuing stimulant medication and monitoring vital signs at each follow-up visit 1, 2
For moderate symptoms or concerning vital sign changes, consider dose reduction or switching to alternative stimulant formulation 5
For severe or persistent symptoms despite dose adjustment, consider switching to non-stimulant medication, such as atomoxetine, extended-release guanfacine, or extended-release clonidine 1, 2, 3, 4

The American Academy of Pediatrics recommends not discontinuing effective medication prematurely based solely on subjective palpitations without objective vital sign assessment 1, 2
Routine ECGs should not be ordered in all patients with palpitations if cardiac history is negative and vital signs show only mild changes 1, 2

Premature atrial beats are common findings in healthy individuals, including those without cardiac disease, and do not predict adverse cardiovascular outcomes in the absence of structural heart disease and thyroid dysfunction 6, 7
In asymptomatic patients with no structural heart disease and normal thyroid function, occasional supraventricular premature beats on Holter monitoring do not contraindicate psychostimulant therapy for ADHD, according to the European Society of Cardiology 6, 7

Patients with structural heart disease, such as known congenital heart disease, cardiomyopathy, or significant valvular disease, require cardiology evaluation before starting stimulants, as recommended by the European Heart Journal 7
Signs of heart failure, such as cardiac murmurs or symptoms of heart failure, should be assessed during physical examination, and patients with these signs may require further evaluation, according to the American Heart Association, as published in Circulation 8

Low-risk patients with occasional supraventricular beats only, no cardiac symptoms, and normal physical examination can proceed with stimulant therapy, as stated in the European Heart Journal 7
Patients with symptomatic arrhythmias, such as syncope, presyncope, dyspnea, or lightheadedness during palpitations, are considered high-risk and require cardiology evaluation before starting stimulants, according to Circulation 8
Paroxysmal supraventricular tachycardia, rather than just premature beats, requires more comprehensive evaluation, as recommended by the European Heart Journal and the American Heart Association 6, 7, 8

The European Society of Cardiology recommends that patients with paroxysmal supraventricular tachycardia may benefit from electrophysiologic study and potential ablation, which can allow more liberal ADHD therapy afterward 6, 7